Transforming Rare-Disease Research Through Applied Intelligence
Explore how AnnieGuard’s Biology-First Intelligence is redefining precision medicine, improving trial enrollment, and accelerating early detection across rare diseases.
Biomarker-First Patient Identification — Soft-Tissue Sarcoma Case Study
AnnieGuard analyzed 422 soft-tissue sarcoma patients using complete genomic profiling and Biology-First Intelligence. Our platform identified five distinct molecular subtypes aligned to active therapeutic opportunities—accelerating trial enrollment and improving patient-to-trial matching.
The analysis surfaced 312 biomarker-confirmed patients eligible for targeted studies, reducing screen failures by 30–40% and shortening enrollment timelines by 6–9 months.
Key Metrics:
-
105 chromatin-remodeling patients → best outcomes (70% survival)
-
94 TERT+ patients → telomerase vaccine–eligible (1.7× male enrichment)
-
312 TP53 wild-type patients → prioritized for MDM2 inhibitor trials
-
PTEN-enriched geographic clusters → optimized for FIX trial site selection
Confidential & Partner-Focused Intelligence Work
AnnieGuard also supports health systems, research groups, and life-science partners with proprietary Biology-First Intelligence analyses that are not publicly disclosed. These include:
-
Rare-disease patient stratification and eligibility modeling
-
Biological signal detection across multimodal datasets
-
Molecular progression and trajectory mapping
-
Biomarker-first population analyses for clinical trials
-
Geographic and demographic enrichment modeling
-
Platform-driven insights for early detection and risk assessment
To inquire about private collaborations or partner-only intelligence reports, please contact us.